CEO Cameron Reynolds confirmed that the company is actively evaluating partnerships to scale its reach, focusing on its core product pillars. While second-quarter revenue held steady at approximately $0.4 million, the firm significantly tightened its financial belt, cutting operating expenses by 32% compared to the same period last year. This discipline reduced the quarterly operating loss to $4.2 million, an improvement of 34% year-over-year.
In section Releases
VolitionRx Targets Licensing Deals Amid Financial Rebound
With first-half revenue climbing 112% to $1.4 million, VolitionRx is shifting its commercial strategy toward aggressive licensing negotiations. The epigenetics firm is currently courting over a dozen global diagnostic companies, aiming to turn its proprietary liquid biopsy and cancer-detection technologies into recurring royalty streams and milestone payments.
Technological milestones underpin the company's current valuation, which management estimates represents a multi-billion-dollar opportunity. Key developments include a pending clinical manuscript for the Nu.Q Vet feline lymphoma assay, which could trigger a $5 million milestone payment upon publication. Simultaneously, the company is working with the Hospices Civils de Lyon to secure reimbursement for its Nu.Q Lung Cancer test, a critical step toward routine clinical adoption. To bolster liquidity, VolitionRx successfully raised $5.3 million in the second quarter through equity sales and a public offering of shares and warrants.
Comments (0)
No comments yet. Be the first!